Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, has announced the rollout of Nerivio in India. This state-of-the-art, United States Food and Drug Administration (USFDA) approved wearable therapy device offers a drug-free option for managing migraines. Migraine is a prevalent global health challenge, significantly impacting women, who make up about 60% of the 213 million […]
New interim analysis from the pan-European PEARL Phase IV study reveals that Teva Pharmaceutical Industries’ AJOVY (fremanezumab) has led to a significant reduction in monthly migraine days for almost 60% of patients. The migraine prevention drug also showed sustained improvement in disability scores and acute medication use over 12 months. The data further show that […]
Zydus Lifesciences (previously Cadila Healthcare) said that its subsidiary Zydus Pharmaceuticals (USA) Inc. has launched Topiramate Extended-Release Capsules in the US. The launch follows the final approval received by Zydus Pharmaceuticals (USA) from the US Food and Drug Administration (FDA) for marketing Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg. The approved […]
Continental Hospitals has opened Continental Headache Clinic in Hyderabad to provide complete, multi-disciplinary approach for the management and treatment of headache and migraine in both adults and children. Continental Headache Clinic will consist of neurologists, neurosurgeons, psychiatrists, neuroradiologists, sleep specialists, psychologists, and nutritionists, said the Indian multi-specialty, tertiary, and quaternary care facility. The multi-dimensional approach […]
Pfizer has agreed to acquire Biohaven Pharmaceutical, a US-based biopharma company, in a deal worth around $11.6 billion, to gain access to the latter’s dual-acting migraine therapy NURTEC ODT (Rimegepant). As per the terms of the deal, Pfizer will pay $148.5 per share in cash to acquire the shares of the NYSE-listed Biohaven Pharmaceutical which […]
Dr. Reddy’s Laboratories (Dr. Reddy’s Labs) has agreed to divest its US and Canada rights for migraine drug — ELYXYB (celecoxib oral solution) 25 mg/ml, to BioDelivery Sciences International (BDSI) in a deal worth $15 million-plus earn-outs. As per the terms of the deal, the Indian pharma company will be paid $6 million upfront upon […]
Novartis said that a five-year phase 2 clinical trial of migraine prevention drug Aimovig (erenumab-aooe) has delivered strong long-term safety and efficacy results in patients with episodic migraine (EM). The results of the mid-stage trial – NCT01952574 are being presented by the Swiss drugmaker at the 18th Migraine Trust Virtual Symposium. The five-year, open-label treatment […]
Reyvow CENTURION trial results : Eli Lilly and Company (Lilly) said that its migraine drug Reyvow (lasmiditan) has met the co-primary endpoint of a phase 3 clinical trial called CENTURION by delivering pain freedom from migraine attacks at 60 minutes and up to 48 hours. According to the US pharma giant, adults who were given Reyvow […]
Cipla has secured final approval for its abbreviated new drug application (ANDA) for Dihydroergotamine Mesylate Nasal Spray 4mg/mL from the US Food and Drug Administration (FDA) with a competitive generic therapy (CGT) designation. The Indian pharma company said that it is the first approved applicant for such CGT and as a result is eligible for […]
Ubrelvy FDA approval : Irish pharma company Allergan has bagged approval from the US Food and Drug Administration (FDA) for Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura in adults. Aura is a sensory phenomenon or visual disturbance. Ubrelvy is now the first orally-administered calcitonin gene-related peptide (CGRP) receptor […]